Chest & Sleep Medicine Associates
Clinical Update for Referring Physicians · Asthma Exacerbations · Week 4 of 4
From the Chest & Sleep Team
Dennis Hoffman
Dennis Hoffman MD
Kumar Gaurav
Kumar Gaurav Physician
Celestia Nielsen
Celestia Nielsen NP
Natalia Angelov
Natalia Angelov FNP-BC

ICS Cuts Exacerbations About 55%

The prevention evidence, the referral thresholds, and what happens when you send us a patient

A question before the clinical note
How many rescue-inhaler canisters per year is associated with increased exacerbation and mortality risk?
A.Three or more for exacerbation risk; twelve or more for mortality risk
B.Six or more for both
C.Twelve or more for both
Answer · A Three or more canisters a year raises exacerbation risk; twelve or more raises the risk of death from asthma (Kew et al., Cochrane, 2022).

Colleagues,

One number carries the argument: inhaled corticosteroid treatment reduces clinically relevant exacerbations by roughly 55% versus placebo or a rescue inhaler alone.

Prevention is not about better rescue medicine. It is about treating the inflammation between the attacks.

55%
fewer clinically relevant exacerbations with inhaled corticosteroid treatment versus placebo or rescue inhaler alone (Sin et al., JAMA, 2004).

Rescue-inhaler-only treatment is no longer recommended. A patient collecting a canister a month is telling you something before they ever present acutely.

Also well supported (GINA 2026)
Guided self-management with a written action plan
Smoking and vaping cessation
Immunizations
Treating allergic rhinitis, sinusitis, reflux, obesity and obstructive sleep apnea
Confirmed food allergy management
Specialist referral for severe asthma
Worth referring
Repeated acute presentations or any hospitalization
Frequent or maintenance OCS
Rescue inhaler overuse at the thresholds above
Difficulty confirming the diagnosis
Symptoms suggesting an infective, cardiac or bronchiectatic cause
Significant multimorbidity

Specialist follow-up after an acute presentation is associated with fewer subsequent ED visits and hospitalizations (GINA 2026). That is the honest case — not that we do something you cannot, but that the follow-through is what reliably falls through the cracks.

When you refer: full pulmonary evaluation, diagnosis confirmed, technique and adherence assessed properly, comorbidities treated, a controller regimen and written action plan built. Where severe asthma is confirmed, phenotyping and biologic evaluation follow. You get a findings note back.

Refer your toughest asthma patient
Send us the patient who keeps coming back, the one on their third canister this year, or the one you cannot get a clean diagnosis on.
Call (847) 860-7250 —say “Code A1026”
Thank you Thank you for the referrals — and for reading along these four weeks.
—Dennis Hoffman, MD · Chest & Sleep Medicine Associates. Sources: Sin et al., JAMA, 2004; Kew et al., Cochrane, 2022; Reddel et al., GINA 2026.
Chest & Sleep Medicine Associates
755 S. Milwaukee Ave, Suite 181, Libertyville, IL 60048
(847) 860-7250  |  chestandsleep.com  |  referrals@chestandsleep.com
You are receiving this because you are a referring provider in our network. Unsubscribe anytime.